NCT04911478View on ClinicalTrials.gov

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Enrolling by invitationOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

August 31, 2038

Study Completion Date

August 31, 2039

Conditions
Lymphoma, FollicularLymphoma, Mantle-CellMarginal Zone LymphomaPrimary Mediastinal B-cell LymphomaDiffuse Large B Cell LymphomaLymphoma, Non-Hodgkin
Interventions
GENETIC

ADI-001

No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy

Trial Locations (5)

40207

Norton Cancer Institute, Louisville

53226

Medical College of Wisconsin, Milwaukee

75204

Baylor Scott & White Research Institute, Dallas

77030

MD Anderson Caner Center, Houston

94305

Stanford University Medical Center, Stanford

Sponsors
All Listed Sponsors
lead

Adicet Therapeutics

INDUSTRY

NCT04911478 - Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | Biotech Hunter | Biotech Hunter